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and found that >60% of CAPAN1 and >40% of DU145 were
killed after an initial treatment but were resistant to subse-
quent treatment. Importantly IHC analysis of these resistant
tumor cells demonstrated lack of expression of the targeted
antigen, MUC1. This observation was conﬁrmed in an artiﬁ-
cial model using 293T cells engineered to express either
MUC1 (mOrange+) or PSCA (GFP+), which illustrated an
exquisite speciﬁcity of T cells but at the same time a weak-
ness when targeting a heterogeneous tumor cell population.
Therefore we generated a second CAR targeting the TAA
PSCA, and demonstrated stable expression on primary T cells
(892%), whichwere able to kill the PSCA+ cell lines, CAPAN1
and DU145, with no effect on control PSCA- 293T, (486%,
4146% and 42% speciﬁc lysis, respectively, 10:1 E:T).
Finally, we assessed the anti-tumor effects when both CAR-
modiﬁed products were combined. When tumor cells
expressing both TAAs were treated with CAR-MUC1 + CAR-
PSCA T cells we saw additive anti-tumor effects with 7610%
killing of CAPAN1 compared with only 356% and 486%,
respectively, using CAR-MUC1 and CAR-PSCA T cells indi-
vidually. We saw similar results using our engineered 293T
tumormodel. Hence the combination of CARs that target two
distinct TAA expressed on cancer cells (PSCA andMUC1) may
prevent tumor immune escape and enhance the potency of
adoptive T cell transfer.478
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Background: Medulloblastoma is the most common brain
tumor in children and its prognosis is improved by the
combination of surgical resection, irradiation, and/or
chemotherapy. Chemotherapy followed by autologous
peripheral blood stem cell (auto-PBSC) rescue has been used
for the treatment of high-risk medulloblastoma.
Patients & Methods: Between July 2010 and July 2012, 8
patients with high-riskmedulloblastoma underwent tandem
chemotherapy with stem cell rescue procedures imple-
menting one of two protocols. Four children aged less than
36 months old [median age 30 month old (range 24-33
months old)] (group-A) received the Children's Oncology
Group e ACNS0334 protocol. The other 4 patients aged more
than 36 months old [median age 12 year old (range 9-15
years old)] (group-B) were treated according to the St. Jude -
SJMB03 protocol.
Results: All patients engrafted well and are alive with no
evidence of disease. Median follow-up from discharge for
last transplant is 6.5 months (range 3-24 months). Neither
cardio nor pulmonary toxicities were documented. Gastro-
intestinal tract: No patient had veno-occlusive disease of the
liver. All patients developed mild to moderate mucositis,
thus received total parentral nutrition for a median period of
7 days (range 5-12 days). Infections: group-A: all patients
experienced at least 1 transplant period without any fever.
Bacteremia included staphylococcus Coa. (-), proteus sp. and
pseudomonas sp. Neither viral nor fungal infections were
documented. Group-B: 2 patients experienced at least 1
transplant without any fever. Bacteremia included staphy-
lococcus Coa. (-), staphylococcus aureus and pseudomonassp. Metabolically: 2 group-B patients developed inappro-
priate anti-diuretic-hormone secretion. All patients devel-
oped mild hypomagnesaemia. Neurology: 1 group-B patient
developed generalized motor weakness attributed to MESNA
he received for the cytoxan. From then on, cytoxanwas given
without MESNA but with urinary catheterization and
hyperhydration. He also developed mastication movements
attributed to the resperidal he got, which was stopped with
improvement. No patient developedmajor bleeding. Renal: 1
group-A patient received VP-16 instead of carboplatine on
the ﬁrst transplant due to basic renal impairment. 1 group-B
patient suffered from renal impairment with GFR reduction
between 25%-50% of baseline following his ﬁrst transplant.
He also demonstrated grade-3 ototoxicity and thus received
only 50% cisplatin dose from the third transplant. Another 2
group-B patients suffered from grade 4 ototoxicity before
admission and therefore did not get cisplatin at all.
Conclusions: Tandem auto-PBSC transplants are feasible for
high-risk medulloblastoma pediatric patients, with excellent
engraftment and survival results and acceptable toxicities,
applying the ACNS0334 and SJMB03 protocols.479
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Adoptive T-cell immunotherapy for solid tumors though
promising has shown limited efﬁcacy in clinical studies. The
hindrance to achieving an objective and durable therapeutic
response is, in part, mediated by the dynamic nature of the
tumor and its complex microenvironment. Tumor-directed
therapies fail to eliminate components of the microenvi-
ronment, which can reinstate a tumorigenic milieu and
contribute to recurrence. Cancer associated ﬁbroblasts
(CAFs), the most preponderant cell type in the microenvi-
ronment, contribute to desmoplasia, tumor growth and
therapeutic resistance. CAFs express ﬁbroblast activation
protein alpha (FAP), a membrane bound serine protease, in
a number of a solid tumors making it an attractive immu-
notherapeutic target. We hypothesized that targeting CAFs
with FAP-speciﬁc T cells will destroy the 'tumor promoting
haven', resulting in signiﬁcant anti-tumor effects.
To test this hypothesis, we successfully generated FAP-
speciﬁc T cells using a second-generation chimeric antigen
receptor (CAR) speciﬁc for FAP. A prototypical CAR combines
the antigen speciﬁcity of an antibody with the signaling
function of a T-cell. The resulting genetically engineered FAP-
speciﬁc T cells recognized and killed human as well as
murine FAP-positive target cells ex vivo. FAP-speciﬁc T cells
also led to a signiﬁcant decrease of FAP-positive murine lung
stromal cells with a concomitant reduction in A549 lung
tumor growth and improved survial when administered
systemically into SCID mice. Targeting FAP-positive CAFs
alone, therefore induces a signiﬁcant anti-tumor response
indicative of its important role in tumor progression.
Finally, given the reciprocal relationship between tumor cells
and CAFs, we hypothesized that co-targeting these two
compartmentswould result in enhancedanti-tumor response
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tocellular carcinoma-A2 (EphA2)-speciﬁc CAR T cells were
used to target the A549 tumor cells. EphA2-speciﬁc T cells
when administered together with FAP-speciﬁc T cells, resul-
ted in a signiﬁcant decrease in tumor growth and increased
survival compared tomice that receivedeither EphA2-or FAP-
speciﬁc T cells alone. Our study underscores the value of co-
targeting both CAFs and cancer cells to increase the beneﬁts of
T-cell immunotherapy for solid tumors.
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There is a growing interest in CD133 antigen expressing stem
cell in the ﬁeld of regenerative medicine such as cardiovas-
cular, peripheral artery, and liver disease. Investigators in
particular concentrate on bone marrow-derived stem cells
for these applications. Today the clinical scale enrichment of
CD133+ cells has to be performed as a complex procedure
involving numerous manual handling steps.
We have developed a fully automated clinical scale process
withinaclosedsterile systemtopurifyCD133+cells fromhuman
bone marrow aspirates. In this context, erythrocyte reduction,
generation of autologous plasma, labeling time and the condi-
tions for immunomagnetic separationwere optimized.
To determine the process performance, CD133+ cells were
separated from human bonemarrow aspirates with an initial
volume of about 60 mL (n¼10). We performed colony-
forming unit (CFU) assays, which allowed us to evaluate the
differentiation potential of the enriched cells.
The total processing time was reduced from about 4.5 h
(previous manual process) to 2.5 h. The number of enriched
CD133+ cells was 7.9x105 (range: 3.7x105 to 1.9x106). The
average yield was 47% and the average viability of the sepa-
rated CD133+ cells achieved 90% (range: 69.9% to 96.9%). The
depletion of CD133 negative cells was >99.9%. CFU assays
perfomed after the fully automated enrichment process
showed that the CD133+ cell fraction contained primitive and
multipotentprogenitorcells, suchasCFU-GEMMandCFU-GM.
The cell separation system described provides a safe and easy
way to purify CD133+ cells from bone marrow aspirates
within 2.5 h without any intermediate manual steps. The cell
preparation in a closed sterile system facilitates a fast and
robust enrichment of CD133+ cells. The cells are eluted in
a small volume (6 mL) and can be used directly for further
applications according to requirements e.g. for use in
regenerative medicine.
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Background: Delayed healing of skin wounds is a major
morbidity. Repeated wounding is characteristic in patients
with recessive dystrophic epidermolysis bullosa (RDEB),
caused bymutations in COL7A1 gene. Stem cell therapy offers
an option in treating this disease (Kiru/Cairo et al. PNAS,
2011). Recently, cord blood (CB) derived pluripotent stem
cells, USSCs, have been applied in several animal models of
degenerative diseases with beneﬁcial outcomes.
Goal: To determine the potential of USSCs in the treatment of
RDEB and its associated wounding phenotype.
Method: CB-USSCs were characterized for genetic and
functional properties. Their in vivo functions were evaluated
in a murine full-thickness excisional wound healing model
and by bioluminescent imaging (BLI), using USSCs modiﬁed
with a luciferase reporter gene.
Results: CB-USSCs share several embryonic stem cell prop-
erties and could be induced to express hallmark genes of
keratinocyte differentiation. USSCs constitutively express
Col7A1, supporting their therapeutic potential in the treat-
ment of patients with RDEB. In the wounding model, a single
USSC intradermal injection promoted epithelialization and
facilitated formation and remodeling of epidermis, accom-
panied by a signiﬁcantly accelerated rate of wound healing
on days 6-10 post wounding (F(1,168)¼50.8 P< .01). In vivo BLI
revealed speciﬁc migration of USSCs from a distant intra-
dermal injection site toward the wound, as well as following
systemic injection. Temporal quantiﬁcation on the total
bioluminescence indicated an overall 59.9% signal loss over 3
days followed by a 95.06% loss at 1 week. The biolumines-
cence in the area of wound was then maintained atw0.5-1%
level till the end of the experiment (3 month). USSCs express
several chemokine receptors that may mediate their migra-
tion to the wound, including CXCR4 (for SDF1), CCR7 (for
CCL21) and PDGFRa (for HMGB1). In vitro chemotaxis assays
indicated that SDF-1 signiﬁcantly enhanced USSC migration
at a concentration of 100ng/ml, while neither CCL21 nor
HMGB1 showed signiﬁcance even at a concentration of 10mg/
ml. The effects of such chemokine/receptor interactions on
USSC recruitment in vivo are now being investigated.
Conclusion: These results suggest signiﬁcant beneﬁcial
effects of CB-USSCs on wound healing and raised the possi-
bility of USSC's therapeutic beneiﬁt in the treatment of
patients with RDEB.
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Introduction: There are several hematopoietic-stem cells
(HSCs) thawing methods for bone marrow reconstitution.
They intend to avoid cell death and patient's side effects due
to the dimethyl sulfoxide (DMSO). We propose another
thawing method that diminishes cell death and therefore
a more rapid hematological recovery.
Material and Methods: The standard thawing-removing
DMSO method for cord blood units was described by
